• In recent weeks, Boston Scientific reported solid year-on-year revenue growth but issued softer guidance, as management flagged slowing U.S. Watchman device sales and intensifying cardiac market competition, prompting some analysts to downgrade the company.
• At the same time, the company announced positive pivotal FRACTURE IDE trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter, highlighting how strengths in its coronary portfolio may balance weakness in parts of its structural heart business.
• Against this backdrop of upbeat SEISMIQ trial data but weaker Watchman expectations, we’ll examine how these shifts affect Boston Scientific’s investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Boston Scientific Investment Narrative Recap

To stay invested in Boston Scientific, you have to believe in its diversified device portfolio and ongoing clinical innovation, while accepting that key franchises like Watchman can face sudden slowdowns. Right now, the main short term catalyst is whether management can stabilize confidence around its cardiac portfolio after weaker Watchman guidance and recent price pressure, while the biggest risk is that intensifying competition and reimbursement or recall issues further weigh on expectations.

The recently reported positive pivotal FRACTURE IDE trial results for the SEISMIQ 4CE coronary intravascular lithotripsy catheter are especially relevant, because they underline the depth of Boston Scientific’s coronary and complex vascular offering at a time when parts of its structural heart business are under scrutiny. For investors watching catalysts, SEISMIQ adds fresh clinical support to the coronary portfolio just as the market is rethinking how much weight to put on Watchman growth.

Yet despite this clinical progress, investors should still be aware that...

Boston Scientific's narrative projects $26.0 billion revenue and $4.9 billion earnings by 2029. This requires 8.1% yearly revenue growth and about a $1.3 billion earnings increase from $3.6 billion today.

Uncover how Boston Scientific's forecasts yield a $79.40 fair value, a 66% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming Boston Scientific could reach about US$28.0 billion in revenue and US$6.0 billion in earnings by 2029, yet the latest Watchman slowdown and competitive pressures could prompt them to rethink how much risk they are taking on that growth path, so it is worth comparing those bullish assumptions with how you view the company’s prospects yourself.

Explore 6 other fair value estimates on Boston Scientific - why the stock might be worth just $78.87!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.